Evidence map›Paper›PMID 25137225›Full record

ReviewProteomics2015

From pathways to networks: connecting dots by establishing protein-protein interaction networks in signaling pathways using affinity purification and mass spectrometry.

Xu Li, Wenqi Wang, Junjie Chen

Abstract readReview
In one paragraph

Review in Proteomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction.Chemical communications (Cambridge, England) · 2024
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xu LiDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wenqi Wang
Junjie Chen

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Analysis of BRCA1 Function in DNA RepairR01CA089239 · NCI · YALE UNIVERSITY · PI CHEN, JUNJIE · 2001 to 2015
$3.7M
Study the Role of DNA Damage Responses in Tumorigenesis and SenescenceR01CA092312 · NCI · YALE UNIVERSITY · PI CHEN, JUNJIE · 2001 to 2015
$3.5M
NCI NIH HHS CA016672NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA089239NCI NIH HHS R01 CA092312
6 · The paper itself

Abstract

Signal transductions are the basis of biological activities in all living organisms. Studying the signaling pathways, especially under physiological conditions, has become one of the most important facets of modern biological research. During the last decade, MS has been used extensively in biological research and is proven to be effective in addressing important biological questions. Here, we review the current progress in the understanding of signaling networks using MS approaches. We will focus on studies of protein-protein interactions that use affinity purification followed by MS approach. We discuss obstacles to affinity purification, data processing, functional validation, and identification of transient interactions and provide potential solutions for pathway-specific proteomics analysis, which we hope one day will lead to a comprehensive understanding of signaling networks in humans.

Indexed as

Protein Interaction MapsSignal TransductionAnimalsChromatography, AffinityHumansMass SpectrometryProtein Interaction MappingProteinsProtein Serine-Threonine KinasesProteomicsProteinsProtein Serine-Threonine KinasesAffinity purificationAnimal proteomicsHippo signalingMass spectrometryProtein-protein interactionSignaling pathways

Identifiers

PMID25137225
PMCPMC4482759

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.